Sequencing endocrine treatment in metastatic luminal breast cancer and alpelisib for treatment of metastatic BC
Sequencing endocrine treatment in metastatic luminal breast cancer and alpelisib for treatment of metastatic BC
Nurse's perspective on PARP inhibitors and personalised medicine in prostate cancer
ITACA NSCLC study: Final results
KEYNOTE-598: pembrolizumab with ipilimumab or placebo in patients with untreated metastatic NSCLC
TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair alterations and mCRPC
ASCO GU 2021: Renal cancer roundup
OncoAlert and ecancer weekly roundup for February 07 - 13, 2021
OncoAlert and ecancer weekly roundup for February 01 - 06, 2021
Latest in EGFR-positive NSCLC with exon 20 insertion mutations
WCLC 2020 overview
Emergence of PARP inhibitors in prostate cancer
Advances and treatment strategies for metastatic hormone-sensitive prostate cancer